The purpose of this study was to assess risk factors for mesh exposure in sacrocolpopexy patients and to determine if ultralightweight polypropylene (Restorelle Ò ) mesh impacted rates of mesh exposure.
3 Polypropylene mesh predicts mesh exposure after sacrocolpopexy independent of known risk factors: A retrospective case-control study ) , were confirmed by our study. New predictors for mesh exposure included prior surgery for incontinence and more immediate perioperative complications. Both mesh choice and suture selection remained important independent predictors of mesh exposure with heavier meshes increasing and monofilament suture decreasing rates of mesh exposure. Based on this study, surgeons should consider use of delayed-absorbable, monofilament suture over non-absorbable, braided suture for attachment of vaginal mesh to reduce the risk of mesh exposure when using ultra-lightweight mesh.
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Paula Durst: Nothing to disclose; Michael Heit: Nothing to disclose. OBJECTIVES: Enhanced Recovery After Surgery (ERAS) pathways are novel, multidisciplinary mechanisms to achieve value-based improvements in surgical care. However, as we strive for better care at lower costs, we must safe guard against compromises in patient safety. Our study objective was to examine the impact of ERAS pathway participation on patient outcomes and adherence to core safety measures among women undergoing laparotomy with a gynecologic oncologist. MATERIALS AND METHODS: A retrospective review of women undergoing laparotomy by a gynecologic oncologist during the inaugural 6 months of ERAS pathway implementation at our institution was conducted. The ERAS pathway was formally implemented by a multidisciplinary Comprehensive Unit Safety Program (CUSP) at our institution. Patient demographic, surgical, and post-operative variables were collected. Patient outcomes including opioid requirements, length of stay, readmission rates, and complication rates were examined according to ERAS pathway participation. Adherence to core safety measures including preoperative antimicrobial and venous thromboembolism (VTE) prophylaxis was also monitored and compared between patients on and off the ERAS pathway. Statistical analyses were performed using t-tests for continuous normally distributed variables, Wilcoxon rank sum tests for skewed continuous variables, and Chi squared tests for categorical variables. RESULTS: A total of 106 consecutive laparotomies were included in this analysis. Half were enrolled in ERAS and 40% received all ERAS bundle interventions. There was no statistical difference in age, BMI, race, cancer status, or procedure performed between the ERAS vs non-ERAS cohorts. ERAS pathway participants benefited from a significantly shorter inpatient hospitalization (4 vs. 5 days, p ¼ 0.04) and utilized 75% fewer narcotics after surgery (448 vs. 112 morphine equivalents, p ¼ 0.001). There were no differences in index admission major complication rates (14% for both cohorts) or 30-day readmission rates (14% vs. 8% p ¼ 0.41) between ERAS and non-ERAS patients, respectively. Compliance with preoperative antimicrobial prophylaxis was 100%. However, 23.5% of all patients received substandard preoperative VTE prophylaxis defined as either no or delayed receipt of heparin. The incidence of VTE was 0.94% during this time period. CONCLUSION: Implementation of an ERAS pathway resulted in significant reductions in length of stay and narcotic use by women undergoing laparotomy with a gynecologic oncologist at our institution. However, adherence to all aspects of the ERAS bundle was challenging in all patients and requires extensive prospective auditing and oversight. The CUSP model is well suited to execute pathway implementation and maintenance. 
